Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.56 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297889 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL22435919 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL25896427 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL500367 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL874162 | 1.00 | S1PR5 (0.56) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| Hydrochloric Acid SCHEMBL15567085 | 0.98 | S1PR5 (0.55) | S1PR5S1PR1FUCA1ALDH1A1LTA4H | |
| SCHEMBL15151079 | 0.89 | S1PR5 (0.51) | S1PR5S1PR1FUCA1LTA4HRORC | |
| SCHEMBL15567084 | 0.89 | S1PR5 (0.51) | S1PR5S1PR1FUCA1LTA4HRORC | |
| SCHEMBL4513757 | 0.89 | S1PR5 (0.51) | S1PR5S1PR1FUCA1RORCACHE | |
| SCHEMBL6231248 | 0.88 | S1PR5 (0.65) | S1PR5S1PR1FUCA1ALDH1A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | Imara Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200157108-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-2757103-B1 | PYRROLIDINE-3-YLACETIC ACID DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| EP-2757103-A1 | PYRROLIDINE-3-YLACETIC ACID DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8106072-B2 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-1486500-B1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIA | KYORIN SEIYAKU KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | ASAHINA YOSHIKAZU | 2009-07-09 | — | — | US | disclosed |
| US-7514451-B2 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7153851-B2 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| US-20060264433-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2006-11-23 | — | — | US | disclosed |
| EP-1666477-A1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1486500-A1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIUM | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | CLPP, PRSS1, FOSB | S1PR5 4203/4885S1PR1 4135/4885FUCA1 3491/4885 |
| US-20200157108-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE2A, PDE3B | S1PR5 450/4885S1PR1 713/4885FUCA1 1607/4885 |
| US-20060264433-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | S1PR5 2261/4885S1PR1 2998/4885FUCA1 2231/4885 |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | RPS27L, RPS7, RPSA | S1PR5 4197/4885S1PR1 4210/4885FUCA1 4277/4885 |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE4B, PDE12 | S1PR5 1998/4885S1PR1 2543/4885FUCA1 1851/4885 |
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | RRP15, RRP12, RRS1 | S1PR5 2180/4885S1PR1 2298/4885FUCA1 3526/4885 |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | TYMS, TKT, TPMT | S1PR5 1833/4885S1PR1 2449/4885FUCA1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.